Upcoming Webinars
SPEAKER/S: Professor Jean-Paul Desaulniers
TIME: 8am PDT / 11am EDT / 5pm CEST
SPEAKER/S: Dr. Eliot Morrison, Silence Therapeutics
TIME: 8am PDT / 11am EDT / 5pm CEST
SPEAKER/S: Tiberiu Stan, PhD, Štefan Moravčík, PharmD.
TIME: 8am PDT / 11am EDT / 5pm CEST
SPEAKER/S: Aurélie Goyenvalle, PhD
TIME: 8am PDT / 11am EDT / 5pm CEST
Recent Webinars
Past Webinars
Development of N=1 RNA Therapies in the Netherlands and Europe
After the development of Milasen in the United States, there has been an increase in the development of antisense oligonucleotide therapies for patients with unique mutations.
2021 OTS Annual Meeting Poster Winner Showcase
Date: October 29th, 2021 Time: 7am-9am Pacific/ 10am-12pm Eastern/ 4pm-6pm Central European Time Description: Are you having post-event letdown now that the annual OTS meeting is over? We are too! Join us for this special 2-hour webinar to see presentations by four poster award winners who will talk about ...
Presentations & Networking in a Virtual World
Presenter: Aurélie Lacroix, PhD, Sixfold Bioscience Keith T. Gagnon, Ph.D, Southern Illinois University School of Medicine Date: 25 August 2021 Time: 8am Pacific / 11am Eastern / 5m Central Description: Join us for a presentation of tips & tricks for making the most of your experience with a virtual ...
Maximize Your Involvement in the OTS Community
Presenter: Erin M. McConnell, Ph.D.,University of Ottawa Annemieke Aartsma-Rus, PhD, OTS President,Leiden University Medical Center Date: June 24, 2021 Time: 8am Pacific/11am Eastern/5pm Central European Time Description: Do you study how oligonucleotides can be used as therapeutics? Are you new to the OTS? Are you a trainee in ...
How to test for immune activation by your therapeutic oligonucleotide
Presenter: Arthur M. Krieg, MD, Checkmate Pharmaceuticals Date: 19 April 2018 Description: RNA and DNA oligonucleotides with charged backbones commonly cause immune activation, which can be recognized by appropriate in vitro and/or in vivo testing. Eukaryotic innate immune systems have evolved multiple receptors to detect foreign or self nucleic ...
Designing siRNAs for improving their therapeutic applications
Presenter: Dr. Annabelle Biscans (AstraZeneca) Date: January 27th, 2021 Description: Small interfering RNAs (siRNAs) have the potential to revolutionize medicine due to their potency, duration of effect, and ability to target previously “undruggable” disease genes. The clinical success of siRNAs is dependent on their efficient delivery to disease tissues. ...
Development of N=1 RNA Therapies in the Netherlands and Europe
After the development of Milasen in the United States, there has been an increase in the development of antisense oligonucleotide therapies for patients with unique mutations.
2021 OTS Annual Meeting Poster Winner Showcase
Date: October 29th, 2021 Time: 7am-9am Pacific/ 10am-12pm Eastern/ 4pm-6pm Central European Time Description: Are you having post-event letdown ...
Presentations & Networking in a Virtual World
Presenter: Aurélie Lacroix, PhD, Sixfold Bioscience Keith T. Gagnon, Ph.D, Southern Illinois University School of Medicine Date: 25 August ...
Maximize Your Involvement in the OTS Community
Presenter: Erin M. McConnell, Ph.D.,University of Ottawa Annemieke Aartsma-Rus, PhD, OTS President,Leiden University Medical Center Date: June 24, 2021 ...
How to test for immune activation by your therapeutic oligonucleotide
Presenter: Arthur M. Krieg, MD, Checkmate Pharmaceuticals Date: 19 April 2018 Description: RNA and DNA oligonucleotides with charged backbones ...
Designing siRNAs for improving their therapeutic applications
Presenter: Dr. Annabelle Biscans (AstraZeneca) Date: January 27th, 2021 Description: Small interfering RNAs (siRNAs) have the potential to revolutionize ...
